Personalized Oncogenomics (POG) Program of British Columbia: Utilization of Genomic Analysis to Better Understand Tumour Heterogeneity and Evolution
The genomic heterogeneity of cancers implies that to effectively use targeted therapies the
investigators will need to assess each individual cancer and match it to a biologically
relevant targeted therapy. The investigators will use full genome sequencing to try to
identify cancer "drivers" and corresponding drugs that may inhibit these pathways.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society